Business
RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review
MOUNTAIN VIEW, Calif., August 14, 2025--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced its financial results and business update to shareholders for the second quarter ended June 30, 2025.
About this update from Renovorx, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/1b887b37354a387b629cf80ca701d12a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/EYxWqQR6yC2o1prdy6i._A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/1b887b37354a387b629cf80ca701d12a","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/.AtwaKhh6Ab6KWg_DgDMMA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/1b887b37354a387b629cf80ca701d12a","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Revenue from RenovoCath® device totaled over $400,000 for the Second Quarter 2025","length":81,"tagName":"p","attribs":{}},{"type":"text","content":"As of June 30, 2025, the Company had $12.3 million in cash and cash equivalents","length":79,"tagName":"p","attribs":{}},{"type":"text","content":"Management to host conference call today at 4:30 p.m. ET","length":56,"tagName":"p","attribs":{}},{"type":"text","content":"MOUNTAIN VIEW, Calif., August 14, 2025--(BUSINESS WIRE)--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced its financial results and business update to shareholders for the second quarter ended June 30, 2025.","length":404,"tagName":"p"},{"type":"text","content":""We are pleased to report second quarter 2025 revenue of over $400,000. This growth highlights the strong clinical need and market demand for our patented RenovoCath device as a standalone targeted drug-delivery product among both new and existing customers. We are proud of the initial organic revenue growth over the first two full quarters since launching RenovoCath commercial sales, especially since this was achieved without a dedicated sales and marketing team. With the recent hiring of Phil Stocton as our Senior Director of Sales and Market Development, our goal is to stay lean, while also continuing to build commercialization momentum. We will continue to gather important data about our market (such as such as sales cycles, ac...